Cover Feature: Current Context of Designing Phototheranostic Cyclometalated Iridium (III) Complexes to Open a New Avenue in Cancer Therapy (ChemMedChem 5/2025)

IF 3.4 4区医学 Q2 CHEMISTRY, MEDICINAL ChemMedChem Pub Date : 2025-03-06 DOI:10.1002/cmdc.202580502

Sreelekha U, Uttara Basu, Prof. Priyankar Paira

{"title":"Cover Feature: Current Context of Designing Phototheranostic Cyclometalated Iridium (III) Complexes to Open a New Avenue in Cancer Therapy (ChemMedChem 5/2025)","authors":"Sreelekha U, Uttara Basu, Prof. Priyankar Paira","doi":"10.1002/cmdc.202580502","DOIUrl":null,"url":null,"abstract":"<p>The cover art features an iridium complex with distinct cyclometalated ligands that enhance both bioimaging and therapeutic properties. The illustration also highlights the therapeutic function, where the iridium complex, upon light irradiation, induces apoptosis or cellular damage, representing its targeted cancer-fighting capabilities. The review article presents the current advancements and future potential of cyclometalated iridium (III) complexes as a phototheranostic agent. The finding demonstrates that cyclometalated iridium (III) complexes hold significant promise for both bioimaging and therapeutic purposes, showcasing potent anticancer activity that addresses the limitations of conventional cancer therapies by enabling more effective targeted delivery. More details can be found in article 10.1002/cmdc.202400649 by Priyankar Paira and co-workers.<figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure>\n </p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"20 5","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cmdc.202580502","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cmdc.202580502","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

The cover art features an iridium complex with distinct cyclometalated ligands that enhance both bioimaging and therapeutic properties. The illustration also highlights the therapeutic function, where the iridium complex, upon light irradiation, induces apoptosis or cellular damage, representing its targeted cancer-fighting capabilities. The review article presents the current advancements and future potential of cyclometalated iridium (III) complexes as a phototheranostic agent. The finding demonstrates that cyclometalated iridium (III) complexes hold significant promise for both bioimaging and therapeutic purposes, showcasing potent anticancer activity that addresses the limitations of conventional cancer therapies by enabling more effective targeted delivery. More details can be found in article 10.1002/cmdc.202400649 by Priyankar Paira and co-workers.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

封面特写：设计光疗环金属化铱（III）配合物为癌症治疗开辟新途径的当前背景（ChemMedChem 5/2025）

封面艺术具有具有不同环金属化配体的铱复合物，可增强生物成像和治疗特性。插图还强调了治疗功能，其中铱复合物，在光照射下，诱导细胞凋亡或细胞损伤，代表其靶向抗癌能力。本文综述了环金属化铱（III）配合物作为光治疗剂的研究进展及未来潜力。这一发现表明，环金属化铱（III）复合物在生物成像和治疗方面都具有重要的前景，通过实现更有效的靶向递送，显示出强大的抗癌活性，解决了传统癌症治疗的局限性。更多细节可以在10.1002/cmdc中找到。Priyankar Paira和同事的202400649。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

ChemMedChem 医学-药学

CiteScore

6.70

自引率

2.90%

发文量

280

审稿时长

1 months

期刊介绍： Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.